EE279 Cost-Effectiveness Analysis of Biosimilars and Novel Biologics for Patients With Moderate-to-Severe Psoriasis

Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.578
https://www.valueinhealthjournal.com/article/S1098-3015(24)00693-4/fulltext
Section Title :
Section Order : 10052
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00693-4&doi=10.1016/j.jval.2024.03.578
HEOR Topics :
Tags :
Regions :